Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer

被引:25
|
作者
Hurria, A [1 ]
Hurria, A [1 ]
Brogan, K [1 ]
Panageas, KS [1 ]
Pearce, C [1 ]
Norton, L [1 ]
Jakubowski, A [1 ]
Howard, J [1 ]
Hudis, C [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
关键词
D O I
10.2165/00002512-200522090-00007
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objective: A number of age-related physiological changes contribute to an increased risk of toxicity of cancer chemotherapy in the elderly. One of the most important of these changes is the progressive decline in renal function with aging. We sought to determine the association between calculated creatinine clearance (CLCR) and grade 3 or 4 toxicities during adjuvant chemotherapy in women >= 65 years of age with breast cancer. Design and methods: We identified 1405 patients >= 65 years of age who had been treated for primary invasive breast cancer at Memorial Sloan-Kettering Cancer Center between January 1998 and December 2000. Patients were included in this analysis if they had stage I-III breast cancer and had received adjuvant chemotherapy. Patients were excluded if they had a prior history of breast cancer or chemotherapy, or had no baseline creatinine value available for review. Results: The 126 patients who met our criteria had received either cyclophosphamide, methotrexate and fluorouracil (CMF) [n = 65, mean age 7 1, range 65-78] or an anthracycline-based regimen (n = 61, mean age 69, range 65-79). The majority of patients (97%) had a normal creatinine. CLCR, as calculated by the Cockcroft-Gault and Jeliffe formulas, decreased with increasing age (increased age associated with decreased Cockcroft-Gault [p = 0.02]; increased age associated with decreased Jeliffe [p < 0.01]). In multivariate analysis, after controlling for age and co-morbidity, a CLCR <50 mL/min by the Cockcroft-Gault formula was associated with an increased risk of fever and neutropenia (odds ratio [OR] 3.60; 95% CI 1.00, 12.94; p = 0.05) and a CLCR <50 mL/min by the Jeliffe formula was associated with a trend towards an increased risk of fever and neutropenia (OR 3.30; 95% CI 0.91, 12.33; p = 0.07), grade 3 or 4 haematological toxicity (OR 2.43; 95% CI 0.90, 6.55; p = 0.08), and need for erythropoietin (OR 4.15; 95% CI 0.81, 2.99; p = 0.09). An increase in creatinine (as a continuous variable) was associated with a trend towards an increased risk of grade 3 or 4 haematological toxicity (OR 5.81; 95% CI 0.96, 35.33; p = 0.06). Conclusions: In this cohort of older breast cancer patients, a decreased CLCR and increased creatinine was associated with an increased risk of fever and neutropenia or haematological toxicity. CLCR should be considered when determining chemotherapy dosage in the elderly.
引用
收藏
页码:785 / 791
页数:7
相关论文
共 50 条
  • [1] Effect of Creatinine Clearance on Patterns of Toxicity in Older Patients Receiving Adjuvant Chemotherapy for Breast Cancer
    Arti Hurria
    Anju Hurria
    Kelly Brogan
    Katherine S. Panageas
    Carol Pearce
    Larry Norton
    Ann Jakubowski
    Jane Howard
    Clifford Hudis
    Drugs & Aging, 2005, 22 : 785 - 791
  • [2] Effect of creatinine clearance (CrCl) on patterns of toxicity in breast cancer (BC) patients (pts) age 65 and older receiving adjuvant chemotherapy.
    Hurria, A
    Panageas, K
    Brogan, K
    Norton, L
    Howard, J
    Hudis, C
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S160 - S160
  • [3] Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy
    Arti Hurria
    Kelly Brogan
    Katherine S. Panageas
    Carol Pearce
    Larry Norton
    Ann Jakubowski
    Marjorie Zauderer
    Jane Howard
    Clifford Hudis
    Breast Cancer Research and Treatment, 2005, 92 : 151 - 156
  • [4] Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy
    Hurria, A
    Brogan, K
    Panageas, KS
    Pearce, C
    Norton, L
    Jakubowski, A
    Zauderer, M
    Howard, J
    Hudis, C
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 92 (02) : 151 - 156
  • [5] Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer (BC)
    Klepin, Heidi D.
    Pitcher, Brandy
    Ballman, Karla V.
    Kimmick, Gretchen Genevieve
    Kornblith, Alice B.
    Cohen, Harvey Jay
    Hurria, Arti
    Winer, Eric P.
    Hudis, Clifford
    Muss, Hyman Bernard
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support
    Wolff, AC
    Jones, RJ
    Davidson, NE
    Jeter, SC
    Stearns, V
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) : 2392 - 2394
  • [7] Adjuvant chemotherapy in older patients with breast cancer
    Agnes Jager
    Jaap Verweij
    Stefan Sleijfer
    Nature Reviews Clinical Oncology, 2009, 6 : 563 - 565
  • [8] Adjuvant chemotherapy in older patients with breast cancer
    Jager, Agnes
    Verweij, Jaap
    Sleijfer, Stefan
    NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (10) : 563 - 565
  • [9] Sleep patterns of women receiving adjuvant chemotherapy for breast cancer
    Erickson, J
    Lyon, D
    Taibi, D
    Kennel, S
    ONCOLOGY NURSING FORUM, 2005, 32 (01) : 184 - 184
  • [10] Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support - Reply
    Burstein, Harold J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) : 2394 - 2395